For the inhibition experiments, the following inhibitors were added to the medium at the indicated concentrations, based on concentrations used in similar studies: GsMTx4 (10 μM), TRPV4 agonists GSK1016790A (G101; 100 nM) and 4α-PDD (20 μM) and TRPV4 antagonist GSK205 (G205, 10 to 30 μM), NHE inhibitor EIPA (50 μM), MEK/ERK inhibitor PD98059 (10 μM), JNK inhibitor SP600125 (10 μM), p38 MAPK inhibitor SB203580 (10 μM), PI3K/Akt inhibitor LY294002 (10 μM), Stat3 inhibitor 5,15-diphenylporphyrin (10 μM), Ras inhibitor Salirasib (10 μM), myosin inhibitor blebbistatin (10 μM), and cell cycle inhibitor at late G1 phase mimosine (400 μM).

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.